Northpointe Capital LLC increased its stake in shares of Genocea Biosciences, Inc. (NASDAQ:GNCA) by 9.6% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,336,062 shares of the biotechnology company’s stock after buying an additional 117,374 shares during the period. Northpointe Capital LLC’s holdings in Genocea Biosciences were worth $6,974,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Ameriprise Financial Inc. boosted its position in shares of Genocea Biosciences by 34.1% in the first quarter. Ameriprise Financial Inc. now owns 19,933 shares of the biotechnology company’s stock worth $121,000 after buying an additional 5,068 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Genocea Biosciences by 4.7% in the first quarter. Geode Capital Management LLC now owns 148,370 shares of the biotechnology company’s stock worth $903,000 after buying an additional 6,708 shares in the last quarter. FMR LLC boosted its position in shares of Genocea Biosciences by 0.4% in the first quarter. FMR LLC now owns 4,274,804 shares of the biotechnology company’s stock worth $26,033,000 after buying an additional 18,574 shares in the last quarter. State of Wisconsin Investment Board acquired a new position in shares of Genocea Biosciences during the second quarter worth approximately $125,000. Finally, Keybank National Association OH acquired a new position in shares of Genocea Biosciences during the first quarter worth approximately $147,000. Institutional investors and hedge funds own 55.20% of the company’s stock.

Shares of Genocea Biosciences, Inc. (NASDAQ GNCA) opened at 4.27 on Wednesday. Genocea Biosciences, Inc. has a 12-month low of $3.28 and a 12-month high of $7.29. The firm’s market cap is $121.87 million. The stock’s 50 day moving average is $5.09 and its 200 day moving average is $5.52.

Genocea Biosciences (NASDAQ:GNCA) last issued its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.54) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.46) by $0.08. Equities analysts expect that Genocea Biosciences, Inc. will post ($1.98) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of US & international copyright & trademark legislation. The original version of this piece of content can be viewed at https://www.watchlistnews.com/northpointe-capital-llc-increases-position-in-genocea-biosciences-inc-gnca/1495116.html.

A number of research analysts have commented on the stock. Zacks Investment Research cut shares of Genocea Biosciences from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. ValuEngine upgraded shares of Genocea Biosciences from a “sell” rating to a “hold” rating in a research note on Monday, July 24th. Piper Jaffray Companies restated an “overweight” rating and set a $18.00 price target (up previously from $17.00) on shares of Genocea Biosciences in a research note on Tuesday, July 25th. Cowen and Company restated an “outperform” rating and set a $40.00 price target on shares of Genocea Biosciences in a research note on Tuesday, July 25th. Finally, Needham & Company LLC upgraded shares of Genocea Biosciences from a “hold” rating to a “buy” rating and set a $12.00 price target for the company in a research note on Monday, July 24th. Two equities research analysts have rated the stock with a sell rating and five have given a buy rating to the company. Genocea Biosciences currently has an average rating of “Hold” and an average target price of $16.52.

In other news, CFO Jonathan Poole sold 45,000 shares of the company’s stock in a transaction that occurred on Monday, July 24th. The shares were sold at an average price of $6.00, for a total transaction of $270,000.00. Following the completion of the sale, the chief financial officer now owns 84,247 shares of the company’s stock, valued at approximately $505,482. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 6.70% of the company’s stock.

Genocea Biosciences Company Profile

Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.

Want to see what other hedge funds are holding GNCA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genocea Biosciences, Inc. (NASDAQ:GNCA).

Institutional Ownership by Quarter for Genocea Biosciences (NASDAQ:GNCA)

Receive News & Ratings for Genocea Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.